Nektar Therapeutics (NKTR) has drawn attention after recent trading saw the stock fall 3.4% in a day and 11.7% over the past week, prompting investors to reassess this US-based biopharmaceutical company.

While Nektar Therapeutics’ share price has fallen 11.7% over the past week and 32.6% over the past month, the year to date share price return of 32% and a very large 1 year total shareholder return suggest earlier momentum is now fading as expectations and perceived risks are reassessed around the current US$57.32 level.

If this kind of sharp swing has your attention, it can be useful to look beyond a single stock and review other healthcare opportunities using our screener for 39 healthcare AI stocks.

With Nektar Therapeutics down sharply in recent weeks but still showing a strong 1 year total return and trading at US$57.32 against a published analyst price target of US$153.25, is there genuine value here, or is the market already pricing in future growth?

Most Popular Narrative: 62.6% Undervalued

At a last close of $57.32 versus a narrative fair value of $153.25, the current price sits well below what this widely followed model implies, putting the focus squarely on the assumptions behind that gap.

Strong initial Phase IIb and ongoing data for REZPEG in atopic dermatitis, combined with a large and growing addressable market (expected to reach nearly $30B by 2033), position Nektar to access significant new revenue streams and improve long-term earnings as the population ages and chronic inflammatory diseases rise globally.

Want to know what kind of revenue path and margin shift are built into that valuation gap? The narrative leans heavily on future sales ramps, margin repair and a premium profit multiple. Curious which assumptions really carry the fair value calculation and how far out the earnings timeline stretches? The full narrative breaks down the numbers and connects them directly to the current $57.32 share price.

Result: Fair Value of $153.25 (UNDERVALUED)

However, the story can change quickly if REZPEG stumbles in later stage trials or if fresh equity funding further dilutes existing shareholders.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another Way to Look at the Valuation

That fair value of $153.25 suggests upside, but the pricing signal from sales tells a different story. Nektar trades on a P/S of 34.8x versus 5.7x for the US Pharmaceuticals industry and 9.3x for peers, while the fair ratio sits at 23.8x, pointing to richer pricing and higher valuation risk. Which signal matters more to you at today’s $57.32?

To see how this pricing gap plays out across peers and what it might mean for future sentiment, take a close look at our valuation breakdown, including the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With a mixed picture of strong recent returns, a sharp pullback and a rich sales multiple, views on Nektar Therapeutics are clearly split. Move quickly, test the assumptions against your own risk tolerance, and weigh both sides by checking the 1 key reward and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities that better match your goals, risk comfort and income needs across the market.

• Spot potential high growth stories early by scanning 24 elite penny stocks with strong financials that combine smaller size with stronger financial profiles than many investors expect.
• Zero in on quality at a reasonable price by reviewing the 49 high quality undervalued stocks that filters for fundamentals and pricing signals in one place.
• Prioritise resilience and staying power by checking the solid balance sheet and fundamentals stocks screener (46 results) designed to highlight companies with sturdier financial footing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.